Inovio Pharmaceuticals specializes in DNA-based immunotherapies for HPV-related conditions, cancer, and infectious diseases. The company's flagship drug, INO-3107, shows promise for treating recurrent ...
Operating Expenses (Q4 2025): $17.5 million, down from $20.5 million in Q4 2024. Full Year Operating Expenses (2025): $86.9 million, a 23% decrease from $112.6 million in 2024. Net Income (Q4 2025): ...
NEW YORK, March 6, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") ...
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results